SCHEMBL13049701

SCHEMBL13049701

Cc1ccc(-c2oc3ccccc3c2CO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.57
▸ TP53 P04637 2/20 0.57
▸ HTT P42858 2/20 0.57
▸ RET P07949 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ ALOX12 P18054 1/20 0.57
▸ KDR P35968 1/20 0.57
▸ ALDH1A1 P00352 5/20 0.51
▸ KDM4E B2RXH2 5/20 0.51
▸ MAOB P27338 2/20 0.45
▸ TNKS O95271 1/20 0.45
▸ PARP1 P09874 1/20 0.45
▸ TNKS2 Q9H2K2 1/20 0.45
▸ PARP2 Q9UGN5 1/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ HPGD P15428 3/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2962849 0.86 KMT2A (0.53) LMNATP53HTTRETTSHR
SCHEMBL13049706 0.85 PTPN1 (0.45) LMNATP53HTTRETTSHR
SCHEMBL13080176 0.84 CYP3A4 (0.42) LMNATP53HTTRETTSHR
SCHEMBL13049690 0.83 MEN1 (0.60) LMNATP53HTTRETTSHR
SCHEMBL13049711 0.83 KDM4E (0.49) LMNATP53HTTRETTSHR
SCHEMBL13049776 0.81 LMNA (0.39) LMNATP53HTTRETTSHR
SCHEMBL13049702 0.81 MEN1 (0.47) LMNATP53HTTRETTSHR
SCHEMBL13049703 0.81 PTGS2 (0.59) LMNATP53HTTRETTSHR
SCHEMBL13049689 0.81 MEN1 (0.47) LMNATP53HTTRETTSHR
SCHEMBL13049721 0.81 MAPK14 (0.49) LMNATP53HTTRETTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
EP-1631561-B1 COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID GEN ELECTRIC (US) 2010-08-18 — — EP disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 LMNA 419/4885TP53 1180/4885HTT 734/4885
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 LMNA 691/4885TP53 977/4885HTT 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback